Network analysis: a new approach to study endocrine disorders

A Stevens^{1,2}, C De Leonibus^{1,2}, D Hanson^{1,2}, A W Dowsey^{1,3}, A Whatmore^{1,2}, S Meyer⁴, R P Donn⁵, P Chatelain⁶, I Banerjee^{1,2}, K E Cosgrove⁷, P E Clayton^{1,2} and M J Dunne⁷

¹Faculty of Medical and Human Sciences, Institute of Human Development, University of Manchester, Manchester, UK

²Manchester Academic Health Science Centre, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, 5th Floor, Oxford Road, Manchester M13 9WL, UK

³Paediatric and Adolescent Oncology, The University of Manchester, Manchester M13 9WL, UK

⁴Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Imaging Sciences, The University of Manchester, Manchester M20 4BX, UK

⁵Musculoskeletal Research Group, NIHR BRU, University of Manchester, Manchester M13 9PT, UK

⁶Department Pédiatrie, Hôpital Mère-Enfant, Université Claude Bernard, 69677 Lyon, France

⁷Faculty of Life Sciences, University of Manchester, Manchester M13 9NT, UK

Correspondence should be addressed to A Stevens
Email
adam.stevens@manchester.ac.uk

Abstract

Systems biology is the study of the interactions that occur between the components of individual cells – including genes, proteins, transcription factors, small molecules, and metabolites, and their relationships to complex physiological and pathological processes. The application of systems biology to medicine promises rapid advances in both our understanding of disease and the development of novel treatment options. Network biology has emerged as the primary tool for studying systems biology as it utilises the mathematical analysis of the relationships between connected objects in a biological system and allows the integration of varied 'omic' datasets (including genomics, metabolomics, proteomics, etc.). Analysis of network biology generates interactome models to infer and assess function; to understand mechanisms, and to prioritise candidates for further investigation. This review provides an overview of network methods used to support this research and an insight into current applications of network analysis applied to endocrinology. A wide spectrum of endocrine disorders are included ranging from congenital hyperinsulinism in infancy, through childhood developmental and growth disorders, to the development of metabolic diseases in early and late adulthood, such as obesity and obesity-related pathologies. In addition to providing a deeper understanding of diseases processes, network biology is also central to the development of personalised treatment strategies which will integrate pharmacogenomics with systems biology of the individual.

Key Words

- modelling
- microarray
- endocrine disruptors
- secretion
- network biology

Journal of Molecular Endocrinology
(2014) 52, R79–R93

Introduction

Network biology has developed as a method to study the many interactions that occur in individual cells, helping to understand the complex biological processes in molecular biology and how they link to integrated

biological systems (Pujol *et al.* 2010). The recent genome sequencing projects have provided a nearly complete list of human gene products and this has been followed by the first drafts of connectivity maps between proteins

A 'Omic' data

- 1 List of proteins, genes, or metabolites from omic data sets
- 2
- 3
- 4

B Interactome model

C Network clusters

D Network topology

E

and gene expression profiles for many different tissues (Parkinson *et al.* 2007). Network biology detects the relationships between different biological components, including genes, proteins, transcription factors, small molecules and metabolites (Arrell & Terzic 2013, Tomar & De 2013), and enables the physical or functional relationships between these components to be identified and interrogated, see Fig. 1 and Box 1. Network analysis can therefore be used to dissect the complexities of biological systems and provide information which is directly relevant to understanding the pathobiology of disorders, including the pathways of disease processes and the prioritisation of candidate disease-causing genes. The aim of this review is to explain how the analysis of biological networks can be carried out and to illustrate how systems biology is impacting on our understanding of diseases, with a particular focus on endocrine conditions which by their very nature are complex and impact upon many organs systems.

Network analysis

How do we visualise biological network models?

The commonest representations of biological networks are 'ball and stick' diagrams. The 'balls' represent proteins or genes and the 'sticks' represent the known interactions. These can be directed, with an arrow representing 'action' or 'flow' of information, or they can be undirected, where connections represent direct associations. Biological networks are 'graphs of connected nodes', where nodes represent biological components, which are connected through edges to show their inter-relationships, from the physical or functional associations to metabolic pathways and regulatory interactions (Arrell & Terzic 2013, Tomar & De 2013; Fig. 1). Several models have been used for network analysis, from 'Power Graphs' and the 'Information Flow Model', to 'Boolean' and 'Bayesian' networks (Missiuro *et al.* 2009, Pujol *et al.* 2010, Youngs *et al.* 2013). In Bayesian networks, the nodes represent biological variables and directed edges represent causality through

conditional probabilities between them. Specifically, they have been used in several fields of systems biology, such as cellular networks inference, pathway modelling, quality assessment of protein–protein interactions and functional annotation of proteins and gene expression analysis (Pujol *et al.* 2010).

Commercially available software for the analysis of gene networks are available (Thomas & Bonchev 2010) and specialise in the 'pattern recognition' of genes clustering within the networks derived from either a previously defined pathway 'cannon' (e.g. Kyoto encyclopedia of genes and genomes (KEGG) database, <http://www.genome.jp/kegg/>) or from a process of network inference algorithmically determined using known biological function (Calvano *et al.* 2005). Most scientists in the life sciences define network analysis based on commercial software of this type, i.e. one in which connections are primarily based on text-mining algorithms. These types of software are designed to be easy to use, provide further quality control of data and have had a major impact on the way in which systems biology analysis is integrated with omic analysis. However, there are advantages to more advanced statistical/computational approaches for generating and analysing networks, primarily around using network properties to prioritise genes for further analysis – these will be covered in more detail in the section 'Computational analysis of molecular interaction networks'.

Analysis of omic datasets: towards integrated analysis

To analyse omic data, two or more contrasting groups are normally compared, such as a 'treated vs control' or 'received dose vs therapeutic response'. A major issue in the analysis of omic datasets with hundreds or thousands of variables is that the number of comparisons is so large that it is likely that the total number of false positives becomes unfavourably high. This phenomenon is moderated by the application of a false discovery rate correction to the statistical test, for example Benjamini–Hochberg correction (Benjamini & Hochberg 1995). However,

Figure 1

Analysis of biological networks. Biological networks can be inferred using (A) 'omic' datasets as 'seeds' by mapping the data to models of all known protein–protein or –genetic interactions and generating an interactome model, (B). The interactome model represents the whole set of known direct and indirect interactions involved with biological topic being studied. By identifying network clusters (C) and measuring network

topology (D), function in the cell system can be inferred and further investigated (E). The same approach can also be used for the prioritisation of omic data for further investigation (E). (D) 'Hubs' are designated 'H' and represent highly connected proteins/genes, and 'bottlenecks' are designated 'B' and represent positions within network with limited connection between clusters.

Box 1 Definitions of technical terminology in network biology.

Bottleneck: corresponds to a network position which limits the performance or the capacity of the system. A network centrality measure representing positions with many 'shortest paths' travelling through.

Cluster modularity: distinct grouping of protein:protein or protein:gene interactions within a network.

Hub: a highly connected node within a network.

Interactome: biological network representing a whole set of direct or indirect interactions related to specific biological function.

Network analysis: relationship of the structural properties of a biological network to function.

Network biology: biology as related to interactions between multiple genes and/or proteins.

Network robustness: a mathematical description of how the integrity of a network responds to the random removal of single nodes.

Node: a protein or gene positioned within a network.

Node centrality: refers to the 'central' positioning of nodes in a network. Central nodes have more ties to the network and determine flow between other nodes.

Seed: known genes used to generate an interactome model from all known protein–protein and –genetic interactions.

Systems biology: integration of complex data about the interactions in biological systems from diverse experimental sources using interdisciplinary tools.

common false discovery rate correction methods assume that comparisons are independent, which is often not the case. Increasingly, extra confidence in the analysis of omic data sets can be provided by observing whether identified changes coalesce into clusters within biological networks (D'Eustachio 2011, Haw *et al.* 2011). These two approaches are not mutually exclusive and are increasingly modelled together to allow interpretation of different types of omic datasets.

Biological networks can be inferred using omic datasets by mapping the data to models of all known protein–protein or –genetic interactions and generating a much larger model of the interactome (Stark *et al.* 2011, Ngounou Wetie *et al.* 2013; Fig. 1). An interactome represents the whole set of direct and indirect molecular interactions involved with the phenomenon being studied (Fig. 1). The interactome model therefore combines data from different omics datasets/databases to generate network cluster maps correlating with the organisation and priority of processes that provide a particular function(s). These models also allow multivariate analysis of the data with consequent gains in statistical certainty (Choi & Pavelka 2011).

The availability of whole genome transcript data has also aided the development of novel approaches to analyse this type of data. For example, it is now possible to incorporate the influence of upstream regulators such as transcription factors and miRNA into modelling of available data. These strategies, in turn, may assist and

strengthen putative mechanisms of disease (Medan *et al.* 2012). It is also possible to fully integrate genetic and transcriptomic analyses by the generation of expression quantitative trait loci (eQTL). An eQTL is a genomic locus that regulates transcription and is defined by mapping methods that examine the linkage between variation in expression and genetic polymorphisms (Kulp & Jagalur 2006, Villa-Vialaneix *et al.* 2013).

Computational analysis of molecular interaction networks

The study of biological networks has increased exponentially over the past 10 years and has been paralleled with the increase in collection and statistical analysis of network-indexed data. Statistical methods to examine the relationship between the properties of biological networks and function have also been developed and research in this area is ongoing (Choi & Pavelka 2011). There are now several analytic methods that are commonly used for relating the structure/topology of biological networks to the functional properties of cells and systems (Toubiana *et al.* 2013). It is well recognised that most biological functions are closed systems at low entropy states and can be resolved to a set of ordered processes. Cluster modularity aims to define this order with the recognition that sub-networks of interconnected nodes might represent molecules which are functionally linked and work in a coordinated manner to achieve a

definite function (Fig. 1C; Gavin *et al.* 2006, Adjari *et al.* 2012, Szalay-Beko *et al.* 2012). Important concepts in analysis include node centrality and network robustness (Barzel & Biham 2009; Box 1 and Fig. 1D). Various mathematical operators are useful in pattern analysis. For example, network motif analysis identifies small networks that are over-represented when compared with a randomised version of the same network (Milo *et al.* 2002), while network alignment and comparison are used to describe similarities between independent networks; this is a type of analysis that has been particularly valuable in understanding the evolutionarily conserved pathways that are common to several organisms (Choi *et al.* 2013). Current software approaches to the assessment of network structure and its relationship to biological function are summarised in Table 1.

Whilst the variety of available approaches to the software analysis of network properties can seem daunting and at the current time have limited consensus of use, 'the ability of these approaches to unravel information not made available via traditional analysis of complex data sets' (as stated by Toubiana *et al.* (2013)) is increasingly being recognised.

Software-based methods in network analysis

Different software-based methods can be used to generate biological networks using omic data as 'seeds', but all use algorithms to infer relationships between omic changes and known interactions in the literature or from open-access databases such as BioDRID (Stark *et al.* 2011, Chatr-Aryamontri *et al.* 2013) and Reactome (Haw *et al.* 2011). Interactome models generated by these methods can be visualised using software such as Cytoscape, which is an open source software platform for the analysis of complex networks (Cline *et al.* 2007, Smoot *et al.* 2011).

Network analysis has also been developed as a process to increase confidence in the observations of differential expression in omic datasets by correlation with biological function (Calvano *et al.* 2005, Werner 2008). This procedure allows the identification of putative key functional elements within the identified networks of differentially expressed genes. Ingenuity Pathway Analysis (IPA) Software is one of the best known examples of this type of approach. Specifically it uses an algorithm which generates inferred networks of omic data by functional similarity (Calvano *et al.* 2005). Both the power and the

Table 1 Some of the main applications in use for the identification of network properties, highly connected network regions, associated biological function and the functional prioritisation of network elements. The majority (all except DAPPLE) are plugins for Cytoscape (Smoot *et al.* 2011)

Application name	Analytical features	References
ModuLand	Uses: analysis of community centrality. An algorithm for determining extensively overlapping network modules. Moreover, it identifies several hierarchical layers of modules, where meta-nodes of the higher hierarchical layer represent modules of the lower layer	Szalay-Beko <i>et al.</i> (2012)
Cytohubba	Calculation of network topological properties. Two characteristic analysis algorithms, Maximum Neighborhood Component (MNC) and Density of Maximum Neighborhood Component (DMNC) are developed for exploring and identifying hubs/essential nodes from interactome networks	Lin <i>et al.</i> (2008)
ClusterONE	ClusterONE (Clustering with Overlapping Neighborhood Expansion) is a graph clustering algorithm that is able to handle weighted graphs and readily generates overlapping clusters	Nepusz <i>et al.</i> (2012)
MCODE	MCODE is an algorithm that finds clusters (highly interconnected regions) in a network	(Bader & Hogue 2003)
NetworkPrioritizer	NetworkPrioritizer provides multiple features to rank individual nodes based on centrality measures according to their relevance to the rest of the network	Kacprowski <i>et al.</i> (2013)
Reactome FIs	Reactome FIs was designed to find network patterns related to condition. Uses community clustering	Newman (2006) and Haw <i>et al.</i> (2011)
DAPPLE	DAPPLE stands for Disease Association Protein-Protein Link Evaluator. DAPPLE looks for significant physical connectivity among proteins encoded for by genes in loci associated to disease according to protein-protein interactions reported in the literature	Rossin <i>et al.</i> (2011) http://www.broadinstitute.org/mpg/dapple/dapple.php

weakness of this approach are that it is based on 'mining' an extensively annotated literature database; this allows highly specific associations to be made but these are only as good as the current database used (Khatri *et al.* 2012). Literature databases have extensive coverage of biological function but can still suffer from distortions in that some interactions may be over- or under-represented (Khatri *et al.* 2012). Interactome modelling generated from the databases of known protein: protein and protein:genetic interactions such as BioGRID (Chatr-Aryamontri *et al.* 2013) suffers from this issue to a lesser extent but requires the more mathematical approaches described in this section to provide functional interpretation.

Analysis of network structure can also be determined by the Cytoscape Software platform, which can be used to provide topological analysis. Topology, a branch of mathematics studying shapes and spaces, is utilised in network analysis to describe network properties such as connectivity, which is an inherent network property involving hubs and bottlenecks (Fig. 1D and Box 1; Lin *et al.* 2008). Using this approach, the top 10–20% of protein–protein interaction network nodes can be ranked for both connectivity and bottleneck scores and then used to generate a minimal essential network (Sun & Zhao 2010, Stevens *et al.* 2013d). A minimal essential network represents the most functionally relevant element of an interactome model and therefore is used to assess biological function (Stevens *et al.* 2013a,b,d).

Disease networks

During the last decade, much effort has been spent in generating a list of disease–gene associations, and explaining how genetic disorders and the corresponding disease–genes might be related (Goh *et al.* 2007, Goh & Choi 2012). However, this process has significant challenges. For instance, diseases can arise from mutations in more than a single gene (locus heterogeneity) and different mutations in the same gene may cause different phenotypes and genetic disorders (allelic heterogeneity) (Goh *et al.* 2007). In order to advance this area, the 'human diseasome' has been generated using network biology, which brings together combined datasets of all known disease–gene associations. This has been created on the basis that there is a cohesive relationship between disease-causing genes and their products, and developed on a conceptual framework which systematically links all recorded genetic disorders (the human disease phenome) with the complete list of known disease-causing genes (the

human disease genome) (Janjic & Przulj 2012). Through the network-based model for the human diseasome, it has been shown that genes that contribute to a common disorder exhibit an increased propensity for their products to co-interact through protein–protein interactions; have a tendency to be co-expressed in specific tissues and share common cellular and functional characteristics, as annotated in gene ontology (Pujol *et al.* 2010, Gene Ontology Consortium 2013).

Disease networks have been created also for orphan diseases that have special consideration as they have a low rate of prevalence. Network relationships based on shared genes or shared functional features have been derived and used to construct the orphan disease-causing mutant gene interactome (Zhang *et al.* 2011). Interestingly, Zhang *et al.* (2011) found that in contrast to the common disease-causing mutant genes that are predominantly non-essential, orphan disease-causing mutant genes are largely essential and are ubiquitously expressed. However, the authors also found that the connectivity of gene-based and other feature-based orphan disease networks is largely different, suggesting that the relationships between diseases cannot be fully captured by the gene-based network alone. As network analysis is evolving through the addition of information to databases, these approaches are nevertheless likely to provide important added value for improved diagnosis, prevention, and discovery of novel therapeutic strategies for orphan diseases.

Disease-focused networks are needed to ensure the validation of multiple biological markers and the understanding of pathophysiology of many diseases (Vlahou 2013). Several examples of disease-focused networks are now emerging, especially in the area of cancer research where numerous cancer cluster gene networks have been described in different types of tumours, including colorectal, ovarian and breast cancers (Bravata *et al.* 2013, Kumar *et al.* 2013b, Yamaga *et al.* 2013, Zhang *et al.* 2013). Network analysis is also leading to promising advances in other fields, including neurological diseases (Parkinson's and Alzheimer's diseases (Balthazar *et al.* 2013, Lones *et al.* 2013, Strafella 2013)) and neuropsychiatric disorders (Kasperek *et al.* 2013); diseases of the immune system (Ivanov & Anderson 2013) including autoimmune or haematologic diseases (Mani *et al.* 2008, Kumar *et al.* 2013a); the pathogenesis of coronary heart diseases (Huan *et al.* 2013), fatty liver diseases (Sookoian & Pirola 2013) and endocrine/metabolic conditions, which will be covered in more detail in the following sections.

Network pharmacology

An improved knowledge of the complex nature of diseases is also beginning to impact upon drug development and to the therapeutic management of diseases (Murthy *et al.* 2013). Whilst most prescribed drugs interact with specific cellular targets, *in vivo* they modify cellular systems through interactions with multiple proteins rather than single entities. Computational modelling of these interactions is now possible and has facilitated a shift towards network-centric strategies in new drug design (Nacher & Schwartz 2008). As a consequence, a novel concept has now emerged in drug discovery for improving treatment responsiveness termed 'polypharmacology' (Barabasi *et al.* 2011) and has been implicated in the design of novel anticancer drugs (Tang & Aittokallio 2013) and antimicrobial agents (Rohde *et al.* 2012).

Analysis of network biology is also helping to understand how the multifaceted interactions between drugs and their cellular targets contribute to efficacy and adverse reactions/side effects. Network pharmacology therefore provides a framework for analysing the actions of drugs on systems, for identifying targets which will modulate disease phenotypes, and for developing therapies that are less vulnerable to drug resistance and side effects (Takarabe *et al.* 2011). Another major area of research in drug discovery is predictive toxicology. Network biology can identify putative secondary targets for a given compound or explore potential downstream effects for blocking or enhancing the actions of key nodes.

Networks analysis of endocrine diseases

In this section, we summarise disease areas in endocrine sciences, which are engaging network analysis to better understand the pathogenesis of disease and the responsiveness of patients to therapy (Fig. 2). In many cases, the

introduction of network analysis to endocrine disorders has come about, because candidate gene approaches to pathogenesis are limited, the phenotype of a particular disease in individuals may be variable and because natural history of a condition is often not inferred from traditional investigations.

Congenital hyperinsulinism in infancy

Congenital hyperinsulinism (CHI) is a rare disease due to dysregulated, excess insulin secretion from pancreatic β -cells, which manifests as profound hypoglycaemia (De Leon & Stanley 2007, Banerjee *et al.* 2013). CHI is the commonest cause of persistent hypoglycaemia in infancy. In contrast to other causes of hypoglycaemia such as infection and hypopituitarism, hypoglycaemia in CHI is unpredictable and severe with a significant adverse impact on future neurodevelopment (Senniappan *et al.* 2012). The condition usually manifests not only in the neonatal period but also later in childhood with milder forms in children who may be able to maintain normoglycaemia on oral feeds. The phenotype of CHI is heterogeneous, with wide variability not only with respect to time of presentation but also the probability of spontaneous resolution vs long-term persistence of disease. Transient CHI resolves spontaneously within weeks to months of diagnosis and accounts for ~50% of all patients (Arnoux *et al.* 2011). Little is known about the cause(s) of hypersecretion of insulin in these patients or the mechanisms responsible for the resolution of symptoms. In contrast to transient disease, the pathophysiology of persistent CHI is far more widely described. So far, mutations in nine genes – *GLUD1*, *SLC16A1*, *HADH*, *UCP2*, *KCNJ11*, *ABCC8*, *HNF1A*, *GCK* and *HNF4A*, are known to associate with persistent CHI, but these only help to understand the process of disease mechanisms in

Figure 2

Network analysis of endocrine diseases. The use of network analysis approaches in a wide spectrum of endocrine conditions in a different set

of age-related groups: from infancy, through childhood to early and late adulthood.

~50% of patients (Banerjee *et al.* 2011, 2013, Senniappan *et al.* 2012). In our studies, computational biology of disease-causing genes has recently been used to seed an interaction network model. Genes integral or tightly connected to the network have been found and represent new candidates for understanding the exact aetiology of this disorder across the spectrum of severities (Stevens *et al.* 2013b).

From the CHI interactome model, cluster analysis of the components of the associated pathways can be carried out (Newman 2006). This analytical approach allows the identification and prioritisation of genes/proteins that are related to mechanisms of disease and may therefore act as biomarkers of CHI for the purposes of diagnosis and disease management (Stevens *et al.* 2013b; Fig. 3).

The largest cluster identified in the CHI interactome model was associated with cellular signalling with 'tropomyosin receptor kinase signalling' as the most significantly related pathway ($P = 5.0 \times 10^{-5}$). Tropomyosin is an integral component of actin filaments within the cytoskeleton. The insulin receptor has been shown to have actions on the structural architecture of the cell (Kadowaki *et al.* 1985) and polymorphism within regulatory regions of the tropomyosin gene has been associated with cytoskeleton-mediated insulin signalling (Savill *et al.* 2010). The second largest cluster found in the CHI interactome model was associated with nuclear signalling and the most significantly related pathway was 'regulation of SMAD2/3 signalling'. SMAD2 has been shown to be associated with the development of pancreatic islets (Goto *et al.* 2007). These observations derived from the network analysis of the CHI interactome model provide prioritisation of network elements for further research.

Human growth and short stature in childhood

Network analysis has been used to demonstrate that the pattern of human growth can be linked to changes in the expression of sets of genes within evolutionarily conserved growth pathways (including *WNT*, *TGFB*, *VEGF* and the *NOTCH* signalling pathways) and that this occurs in a tissue-independent manner (Stevens *et al.* 2013d). This phenomenon has also been shown to occur in rodent models (Finkelstein *et al.* 2009); however, the pattern of human growth and development is distinct from that of other mammals (Bogin 1999, Thompson & Nelson 2011), and is characterised by rapid but decelerating growth in infancy, an extended childhood phase of slow growth and a pubertal growth spurt before final height is reached, termed the infancy-childhood-puberty growth model

(Karlberg *et al.* 2003). Despite extensive experience over the past 25 years in the clinical management of growth failure in growth disorders, including growth hormone deficiency (GHD) and Turner syndrome (TS), predicting treatment efficacy in individual children remains a significant challenge as both age and stage of childhood development are now known to be important predictors of the outcome of treatments (Ranke *et al.* 1999, Ranke *et al.* 2000, Ranke & Lindberg 2011, Patel & Clayton 2012, Ranke 2013).

The possibility of stratifying patients based on genetic variation of response to GH therapy led to the development of the PREDICT study, the aim of which was to assess the genomic profiles of GHD and TS children in response to GH therapy by the analysis of both genetic and transcriptomic data (Clayton *et al.* 2013, Stevens *et al.* 2013a). Integrating gene expression and genetic data has provided mechanistic insight into growth response and helped to support the identification of genes with predictive value of growth response. Insulin-like growth factor 1 (IGF1) production over the first month of treatment (Stevens *et al.* 2013a) and first-year growth responses to recombinant human GH (r-hGH) therapy (Clayton *et al.* 2013) have both been studied using this approach and several growth-related pathways involved in response to GH therapy have been identified beyond the traditional GH and IGF1 signalling pathways. These included the MAPK pathway, a pathway well known to be involved in growth (Yamauchi *et al.* 1997, Hanson *et al.* 2012) but considered to have a less prominent role than the GH pathway. In the MAPK pathway, multiple single nucleotide polymorphisms (SNPs) in genes associated with response to GH therapy were located in both GHD and TS and these genes were shown to be located in network clusters that also contained gene expression changes associated with response to GH therapy. A network analysis using prioritisation by the connectivity of gene expression associated with the carriage of CDK4 alleles linked to IGF1 change over the first month of GH treatment also highlighted the role of the MAPK pathway's response in GHD children (Stevens *et al.* 2013a). From these models, proof of principle has been established, that it is possible to identify genetic biomarkers of growth response which could have important predictive potential.

Obesity and adipose tissue

Adipose tissue is a host to a number of complex regulatory networks, involving growth, metabolism and intracellular signalling pathways. Several systems-led investigations

Figure 3

Human interactome network analysis of CHI-associated genes. (A) Genes with a known association with CHI were used to infer a network from the BioGRID model of the human interactome (<http://thebiogrid.org/>). (B) Biological pathway ontology associated with each network module (colour coded); hypergeometric test false discovery rate (FDR) ≤ 0.001 . The inferred network was generated using the BioGRID plugin for Cytoscape

3.1.93 to identify the primary interactors of CHI genes from all known physical and genetic evidence. Reproduced from Stevens A, Cosgrove KE, Padidela R, Skae MS, Clayton PE, Banerjee I & Dunne MJ 2013b Can network biology unravel the aetiology of congenital hyperinsulinism? *Orphanet Journal of Rare Diseases* 8 21–28.

have been performed to assess regulatory networks within adipose cells. Specific lipid metabolism networks have also been discovered, which have environmental and genetic influences and form a highly regulated and integrated homeostatic network primarily designed to maintain energy homeostasis and tissue growth/expansion (Sethi & Vidal-Puig, 2007). These pathways are relevant to obesity and obesity-associated metabolic dysregulation as adipose tissue plasticity and expandability play an important role in energy homeostasis in health and disease. Metabolomics has been applied to the study of lipid molecules including free fatty acids and phospholipids (Han & Gross 2003). This lipidomic approach has been used to investigate the metabolic regulation of adipocytes in obesity in order to further understand the cascade of events progressing from adipocyte expansion to immune cell recruitment and initiation of inflammation (Kamei *et al.* 2006). Lipidomics utilising network analysis has identified metabolic biomarkers for the response of adipose tissue to treatment. A study on the use of rosiglitazone on lipid metabolism in diabetic mice recently suggested that increased *de novo* synthesis of the fatty acid palmitoleate may have relevance as a biomarker (Watkins *et al.* 2002). Palmitoleate has been shown to be synthesised during lipogenesis and its production correlates with improved insulin sensitivity (Cao *et al.* 2008). In humans, the proportion of palmitoleate was increased in obese but otherwise healthy individuals, suggesting that the production of this fatty acid could reflect an adaptive measure to restore insulin sensitivity. Surprisingly, palmitoleic acid production was not increased in morbidly obese subjects (Pietilainen *et al.* 2011). As obesity has a direct association with systemic inflammation and the secondary development of diseases including atherosclerosis, obesity-related insulin resistance and type 2 diabetes, network analysis has also been used to explore functional connectivity between adipocytes and other metabolic tissues; see sections below.

Obesity and atherosclerosis

Obesity status is often associated with hypercholesterolaemia that leads in turn to an increased risk of atherosclerosis and cardiovascular diseases (Goldstein & Brown 2001). One of the first key events in the development of atherosclerotic plaque is the uptake of oxidised LDLs by macrophages, which leads to local inflammatory reactions and to the formation of lipid-loaded macrophages, termed 'foam cells'. LXRA, is a ligand-dependent nuclear receptor that regulates cholesterol homeostasis and reverses cholesterol transport; therefore, it represents an important drug target.

A recent study has used integrative genomic analysis to understand LXRA-dependent functional characteristics and transcriptional regulation pathways (Feldmann *et al.* 2013). Several SNPs within LXRA-dependent binding sites were found to have differentially expressed target genes involved in the biological processes linked to inflammation, cell growth and apoptosis. To analyse the role of LXRA modulation in atherosclerosis and related diseases, a human macrophage and foam cell network model was used to investigate the actions of a synthetic LXR agonist – T0901317, which has a potential atheroprotective role. By using transcriptional network analysis, highly integrated LXRA ligand-dependent transcriptional clusters were detected which contribute to the reversal of cholesterol efflux and the dampening of inflammation processes in the foam cells (Feldmann *et al.* 2013). An important implication of these data is that network analysis in this field is helping the understanding of molecular mechanisms governing atherogenesis, which has relevance to therapeutic strategies to prevent atherosclerosis.

Obesity and type 2 diabetes mellitus

Current studies based on integrating genotypic data have shown that complex traits such as obesity are modulated by compound networks based on multiple genetic loci and environmental factors. Obesity is also well known to be a chronic tissue inflammation contributing to insulin resistance and secondly to the development of pancreatic β -cell failure and type 2 diabetes mellitus (T2DM). In the USA, the current obesity epidemic is running in parallel with a T2DM epidemic and the underlying pathophysiology are closely linked (Osborn & Olefsky 2012). Several mechanisms proposed to induce β -cell failure have been detected, involved in endoplasmic reticulum stress, oxidative stress, lipotoxicity and glucotoxicity which are mostly mediated by tissue inflammation (Hotamisligil & Erbay 2008, Santiago & Potashkin 2013). A genetics and systems-based approach to the identification of susceptibility loci in obesity-induced diabetes in mice has recently been added to our understanding of the complex genetic interactions contributing to this condition (Davis *et al.* 2012). In this study, loci contributing to diabetes-related traits were identified, and candidate genes for variations in gene expression were prioritised. Co-expression networks for mice at different ages and clinical traits were then generated and several modules found to be tightly associated with obesity-induced diabetes (Davis *et al.* 2012). In a separate study, gene and protein interactome models were generated from gene

expression and metabolic profiling data in obese mice. Network analysis of these models was used to identify differentially activated sub-networks that demonstrated immune system gene networks and inflammatory biomarkers were upregulated in the adipose tissue and that this preceded insulin resistance therefore revealing key links between nutrition and genetic factors (Mori *et al.* 2010).

The recent introduction of genome wide association studies has also led to the identification of several SNPs associated with diseases, including T2DM. Network analysis has now been used to integrate SNPs known to be associated with T2DM with eQTL and this has led to the discovery of several novel candidate genes for T2DM, involved in the regulation and metabolism of insulin, glucose and lipids (Kang *et al.* 2012). Biological network analysis in humans has also revealed an association between T2DM and Parkinson's disease through a network model which places insulin resistance and inflammation central to defects in insulin secretion and defective glucose sensing and impaired insulin signalling, leading to cognitive decline and neurodegeneration (Santiago & Potashkin 2013).

Development of drug-induced insulin resistance: network analysis example of glucocorticoid and GH therapies

The development of insulin resistance and T2DM is not only related to obesity, but can also be iatrogenic. Fleuren *et al.* (2013) have recently reported on the use of gene networks to identify which genes may play a role in the development of insulin resistance induced by glucocorticoids and identified several candidates, including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Treatment with r-hGH can present short-term complications including insulin sensitivity which we have studied in pre-pubertal children with GHD. By network analysis clusters of genes have been identified that underlie metabolic and growth responses to GH and are associated with adipocyte differentiation and cell cycle regulation pathways (Stevens *et al.* 2013c). These approaches can also be applied to a variety of drug-induced disease networks and may help to identify candidate genetic markers for predicting response to treatment and the development of side effects.

Diabetic kidney disease

Diabetic kidney disease (DKD) is a microvascular complication of diabetes mellitus and is usually accompanied by

a progressive loss of kidney function. It has been shown that genetic variations and environmental factors are strongly linked to DKD susceptibility and to the progression of kidney dysfunction (Komorowsky *et al.* 2012, Bhalla *et al.* 2013). The improvement of standardised high-throughput technologies of tissue sampling combined with network analysis of tissues from patients with DKD has now led to a far better understanding of the pathophysiology of DKD. Using human renal biopsies, transcriptomics in tubulo-interstitial compartments has recently been combined with hypothesis-driven network pathway analysis to document the involvement of several genes related to inflammation in progressive DKD (Komorowsky *et al.* 2012). Transcriptional network analysis combined with promoter modelling approaches has also been used to identify a specific NF- κ B module in the pathogenesis of DKD, effectively segregating progressive forms of DKD from mild diabetic nephropathy and control subjects (Schmid *et al.* 2006). Other mechanisms have also been shown to be involved in human DKD, including specific gene expression patterns pointing at pathways involving hypoxic gene regulation, vascular plasticity and JAK/STAT signalling (Lindenmeyer *et al.* 2007, Berthier *et al.* 2009).

Conclusions

We have an unprecedented capacity to generate datasets that can document the detailed and complex interactions that take place within a cell. These are being mapped in incredible detail through a combination of technological advancements in experimental techniques, including the ready availability of second- and third-generation sequencing platforms; associated methods (such as RNA-seq and ChIP-seq); other high-throughput 'omics methods, including quantitative proteomics, interactomics and miRNAomics/MIROMics (Szabo *et al.* 2013) and the application of computational biology to analyse, visualise and model the systems data. Epigenomics, the whole genome study of DNA methylation and histone markers as indicators of transcriptional activity, is also amenable to network analysis, but this has not yet been implemented in an endocrine context. By contrast epigenomic/network biology integration has made important advances to the area of cancer biology (Huang *et al.* 2013).

These technologies promise rapid advances both in the scale at which biological research is performed and in the scope of the questions that can be tackled. However, they also offer new challenges, owing to the volume of data generated. In the last few years, a new situation has

arisen in biology, whereby, in many cases, the rate-limiting step has shifted from data generation to data analysis. Compounding this problem is the fact that many researchers with traditional experimental training lack the computational skills that 'big data' projects require. For this reason, the full potential of these new technologies remains to be fully realised. In this review, we have provided examples of network analysis in endocrinology. Current technology and new approaches to the analysis of omic data can now be combined and network biology can be used to reveal cohesiveness and order from a broad array of datasets representing all aspects of cell function enabling systematic prioritisation and interpretation of the underlying biology of a network. The systems biology approach will undoubtedly enhance understanding of the normal physiology and pathophysiology of different diseases. Interactome modelling of pharmacogenomic responses to therapy will also identify putative new drug targets and possible drug-induced side effects, leading to the introduction of new or repositioned therapeutic agents in clinical practice.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review reported.

Funding

A S was supported by Merck Serono S.A. (Geneva, Switzerland). C L was supported by the University of Manchester and a European Society for Paediatric Endocrinology (ESPE) Research Fellowship, sponsored by Novo Nordisk A/S.

References

- Adjari RA, Sendina-Nadal I, Papo D, Zanin M, Buldu JM, del Pozo F & Boccaletti S 2012 Topological measure locating the effective crossover between segregation and integration in a modular network. *Physical Review Letters* **108** 228701. (doi:10.1103/PhysRevLett.108.228701)
- Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y *et al.* 2011 Congenital hyperinsulinism: current trends in diagnosis and therapy. *Orphanet Journal of Rare Diseases* **6** 63–66. (doi:10.1186/1750-1172-6-63)
- Arrell DK & Terzic A 2013 Interpreting networks in systems biology. *Clinical Pharmacology and Therapeutics* **93** 389–392. (doi:10.1038/clpt.2013.28)
- Bader GD & Hogue CW 2003 An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* **4** 2. (doi:10.1186/1471-2105-4-2)
- Balthazar ML, Pereira FR, Lopes TM, da Silva EL, Coan AC, Campos BM, Duncan NW, Stella F, Northoff G, Damasceno BP *et al.* 2013 Neuropsychiatric symptoms in Alzheimer's disease are related to functional connectivity alterations in the salience network. *Human Brain Mapping* [in press]. (doi:10.1002/hbm.22248)
- Banerjee I, Skae M, Flanagan SE, Rigby L, Patel L, Didi M, Blair J, Ehtisham S, Ellard S, Cosgrove KE *et al.* 2011 The contribution of rapid KATP channel gene mutation analysis to the clinical management of children with congenital hyperinsulinism. *European Journal of Endocrinology* **164** 733–740. (doi:10.1530/EJE-10-1136)
- Banerjee I, Avatapalle B, Padidela R, Stevens A, Cosgrove K, Clayton P & Dunne M 2013 Integrating genetic and imaging investigations into the clinical management of congenital hyperinsulinism. *Clinical Endocrinology* **78** 803–813. (doi:10.1111/cen.12153)
- Barabasi AL, Gulbahce N & Loscalzo J 2011 Network medicine: a network-based approach to human disease. *Nature Reviews Genetics* **12** 56–68.
- Barzel B & Biham O 2009 Quantifying the connectivity of a network: the network correlation function method. *Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics* **80** 046104. (doi:10.1103/PhysRevE.80.046104)
- Benjamini Y & Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society, Series B* **57** 289–300.
- Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B, Boucherot A, Neusser MA, Cohen CD, Carter-Su C *et al.* 2009 Enhanced expression of janus kinase–signal transducer and activator of transcription pathway members in human diabetic nephropathy. *Diabetes* **58** 469–477. (doi:10.2337/db08-1328)
- Bhalla V, Velez MG & Chertow GM 2013 A transcriptional blueprint for human and murine diabetic kidney disease. *Diabetes* **62** 31–33. (doi:10.2337/db12-1121)
- Bogin B 1999 Evolutionary perspective on human growth. *Annual Review of Anthropology* **28** 109–153. (doi:10.1146/annurev.anthro.28.1.109)
- Bravata V, Cammarata FP, Forte GI & Minafra L 2013 "Omics" of HER2-positive breast cancer. *OMICS* **17** 119–129. (doi:10.1089/omi.2012.0099)
- Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK *et al.* 2005 A network-based analysis of systemic inflammation in humans. *Nature* **437** 1032–1037. (doi:10.1038/nature03985)
- Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM & Hotamisligil GS 2008 Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. *Cell* **134** 933–944. (doi:10.1016/j.cell.2008.07.048)
- Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O'Donnell L *et al.* 2013 The BioGRID interaction database: 2013 update. *Nucleic Acids Research* **41** D816–D823. (doi:10.1093/nar/gks1158)
- Choi H & Pavelka N 2011 When one and one gives more than two: challenges and opportunities of integrative omics. *Frontiers in Genetics* **2** 105. (doi:10.3389/fgene.2011.00018)
- Choi J, Kim K, Song M & Lee D 2013 Generation and application of drug indication inference models using typed network motif comparison analysis. *BMC Medical Informatics and Decision Making* **13** (Suppl 1) S2–S13. (doi:10.1186/1472-6947-13-S1-S2)
- Clayton P, Chatelain P, Tato L, Yoo HW, Ambler GR, Belgorosky A, Quinteiro S, Deal C, Stevens A, Raelson J *et al.* 2013 A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome. *European Journal of Endocrinology* **169** 277–289. (doi:10.1530/EJE-13-0069)
- Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B *et al.* 2007 Integration of biological networks and gene expression data using Cytoscape. *Nature Protocols* **2** 2366–2382. (doi:10.1038/nprot.2007.324)
- Davis RC, van Nas A, Castellani LW, Zhao Y, Zhou Z, Wen P, Yu S, Qi H, Rosales M, Schadt EE *et al.* 2012 Systems genetics of susceptibility to obesity-induced diabetes in mice. *Physiological Genomics* **44** 1–13. (doi:10.1152/physiolgenomics.00003.2011)
- De Leon DD & Stanley CA 2007 Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. *Nature Clinical*

- Practice. *Endocrinology & Metabolism* **3** 57–68. (doi:10.1038/ncpendmet0368)
- D'Eustachio P 2011 Reactome knowledgebase of human biological pathways and processes. *Methods in Molecular Biology* **694** 49–61. (doi:10.1007/978-1-60761-977-2_4)
- Feldmann R, Fischer C, Kodelja V, Behrens S, Haas S, Vingron M, Timmermann B, Geikowski A & Sauer S 2013 Genome-wide analysis of LXR α activation reveals new transcriptional networks in human atherosclerotic foam cells. *Nucleic Acids Research* **41** 3518–3531. (doi:10.1093/nar/gkt034)
- Finkelstein GP, Forcinito P, Lui JC, Barnes KM, Marino R, Makaroun S, Nguyen V, Lazarus JE, Nilsson O & Baron J 2009 An extensive genetic program occurring during postnatal growth in multiple tissues. *Endocrinology* **150** 1791–1800. (doi:10.1210/en.2008-0868)
- Fleuren WW, Toonen EJ, Verhoeven S, Frijters R, Hulsen T, Rullmann T, van Schaik R, de Vlieg J & Alkema W 2013 Identification of new biomarker candidates for glucocorticoid induced insulin resistance using literature mining. *BioData Mining* **6** 2–6. (doi:10.1186/1756-0381-6-2)
- Gavin AC, Aloy P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck S, Dumpelfeld B *et al.* 2006 Proteome survey reveals modularity of the yeast cell machinery. *Nature* **440** 631–636. (doi:10.1038/nature04532)
- Gene Ontology Consortium 2013 Gene ontology annotations and resources. *Nucleic Acids Research* **41** D530–D535. (doi:10.1093/nar/gks1050)
- Goh KI & Choi IG 2012 Exploring the human diseasesome: the human disease network. *Briefings in Functional Genomics* **11** 533–542. (doi:10.1093/bfpg/els032)
- Goh KI, Cusick ME, Valle D, Childs B, Vidal M & Barabasi AL 2007 The human disease network. *PNAS* **104** 8685–8690. (doi:10.1073/pnas.0701361104)
- Goldstein JL & Brown MS 2001 Molecular medicine. The cholesterol quartet. *Science* **292** 1310–1312. (doi:10.1126/science.1061815)
- Goto Y, Nomura M, Tanaka K, Kondo A, Morinaga H, Okabe T, Yanase T, Nawata H, Takayanagi R & Li E 2007 Genetic interactions between activin type IIB receptor and Smad2 genes in asymmetrical patterning of the thoracic organs and the development of pancreas islets. *Developmental Dynamics* **236** 2865–2874. (doi:10.1002/dvdy.21303)
- Han X & Gross RW 2003 Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. *Journal of Lipid Research* **44** 1071–1079.
- Hanson D, Murray PG, Coulson T, Sud A, Omokanye A, Stratta E, Sakhinia F, Bonshek C, Wilson LC, Wakeling E *et al.* 2012 Mutations in CUL7, OBSL1 and CCDC8 in 3-M syndrome lead to disordered growth factor signalling. *Journal of Molecular Endocrinology* **49** 267–275. (doi:10.1530/JME-12-0034)
- Haw R, Hermjakob H, D'Eustachio P & Stein L 2011 Reactome pathway analysis to enrich biological discovery in proteomics datasets. *Proteomics* **11** 3598–3613. (doi:10.1002/pmic.201100066)
- Hotamisligil GS & Erbay E 2008 Nutrient sensing and inflammation in metabolic diseases. *Nature Reviews. Immunology* **8** 923–934. (doi:10.1038/nri2449)
- Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, Johnson AD, Ying S, Munson PJ, Raghavachari N, Wang R *et al.* 2013 A systems biology framework identifies molecular underpinnings of coronary heart disease. *Arteriosclerosis, Thrombosis, and Vascular Biology* **33** 1427–1434. (doi:10.1161/ATVBAHA.112.300112)
- Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, Gordon W, Lauffenburger DA & Fraenkel E 2013 Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. *PLoS Computational Biology* **9** e1002887. (doi:10.1371/journal.pcbi.1002887)
- Ivanov P & Anderson P 2013 Post-transcriptional regulatory networks in immunity. *Immunological Reviews* **253** 253–272. (doi:10.1111/imr.12051)
- Janjic V & Przulj N 2012 Biological function through network topology: a survey of the human diseasesome. *Briefings in Functional Genomics* **11** 522–532. (doi:10.1093/bfpg/els037)
- Kacprowski T, Doncheva NT & Albrecht M 2013 NetworkPrioritizer: a versatile tool for network-based prioritization of candidate disease genes or other molecules. *Bioinformatics* **29** 1471–1473. (doi:10.1093/bioinformatics/btt164)
- Kadowaki T, Fujita-Yamaguchi Y, Nishida E, Takaku F, Akiyama T, Kathuria S, Akanuma Y & Kasuga M 1985 Phosphorylation of tubulin and microtubule-associated proteins by the purified insulin receptor kinase. *Journal of Biological Chemistry* **260** 4016–4020.
- Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, Kubota N, Ohtsuka-Kowatari N, Kumagai K, Sakamoto K, Kobayashi M *et al.* 2006 Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. *Journal of Biological Chemistry* **281** 26602–26614. (doi:10.1074/jbc.M601284200)
- Kang HP, Yang X, Chen R, Zhang B, Corona E, Schadt EE & Butte AJ 2012 Integration of disease-specific single nucleotide polymorphisms, expression quantitative trait loci and coexpression networks reveal novel candidate genes for type 2 diabetes. *Diabetologia* **55** 2205–2213. (doi:10.1007/s00125-012-2568-3)
- Karlberg J, Kwan CW, Gelander L & Bertsson-Wikland K 2003 Pubertal growth assessment. *Hormone Research* **60** 27–35. (doi:10.1159/000071223)
- Kasperek T, Prikrýl R, Rehulova J, Marecek R, Mikl M, Prikrýlova H, Vanicek J & Ceskova E 2013 Brain functional connectivity of male patients in remission after the first episode of schizophrenia. *Human Brain Mapping* **34** 726–737.
- Khatri P, Sirota M & Butte AJ 2012 Ten years of pathway analysis: current approaches and outstanding challenges. *PLoS Computational Biology* **8** e1002375. (doi:10.1371/journal.pcbi.1002375)
- Komorowsky CV, Brosius FC III, Pennathur S & Kretzler M 2012 Perspectives on systems biology applications in diabetic kidney disease. *Journal of Cardiovascular Translational Research* **5** 491–508. (doi:10.1007/s12265-012-9382-7)
- Kulp DC & Jagalur M 2006 Causal inference of regulator–target pairs by gene mapping of expression phenotypes. *BMC Genomics* **7** 125. (doi:10.1186/1471-2164-7-125)
- Kumar A, Cocco E, Atzori L, Marrosu MG & Pieroni E 2013a Structural and dynamical insights on HLA–DR2 complexes that confer susceptibility to multiple sclerosis in sardinia: a molecular dynamics simulation study. *PLoS ONE* **8** e59711. (doi:10.1371/journal.pone.0059711)
- Kumar G, Breen EJ & Ranganathan S 2013b Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework. *BMC Systems Biology* **7** 12–17. (doi:10.1186/1752-0509-7-12)
- Lin CY, Chin CH, Wu HH, Chen SH, Ho CW & Ko MT 2008 Hubba: hub objects analyzer – a framework of interactome hubs identification for network biology. *Nucleic Acids Research* **36** W438–W443. (doi:10.1093/nar/gkn257)
- Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP *et al.* 2007 Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. *Journal of the American Society of Nephrology* **18** 1765–1776. (doi:10.1681/ASN.2006121304)
- Lones MA, Smith SL, Tyrrell AM, Alty JE & Jamieson DR 2013 Characterising neurological time series data using biologically motivated networks of coupled discrete maps. *Bio Systems* **112** 94–101. (doi:10.1016/j.biosystems.2013.03.009)
- Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R & Califano A 2008 A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. *Molecular Systems Biology* **4** 169. (doi:10.1038/msb.2008.2)
- Medan D, Luanpitpong S, Azad N, Wang L, Jiang BH, Davis ME, Barnett JB, Guo L & Rojanasakul Y 2012 Multifunctional role of Bcl-2 in malignant transformation and tumorigenesis of Cr(VI)-transformed lung cells. *PLoS ONE* **7** e37045. (doi:10.1371/journal.pone.0037045)

- Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D & Alon U 2002 Network motifs: simple building blocks of complex networks. *Science* **298** 824–827. (doi:10.1126/science.298.5594.824)
- Missiuro PV, Liu K, Zou L, Ross BC, Zhao G, Liu JS & Ge H 2009 Information flow analysis of interactome networks. *PLoS Computational Biology* **5** e1000350. (doi:10.1371/journal.pcbi.1000350)
- Mori MA, Liu M, Bezy O, Almird K, Shapiro H, Kasif S & Kahn CR 2010 A systems biology approach identifies inflammatory abnormalities between mouse strains prior to development of metabolic disease. *Diabetes* **59** 2960–2971. (doi:10.2337/db10-0367)
- Murthy D, Attri KS & Gokhale RS 2013 Network, nodes and nexus: systems approach to multitarget therapeutics. *Current Opinion in Biotechnology* [in press]. (doi:10.1016/j.copbio.2013.02.009)
- Nacher JC & Schwartz JM 2008 A global view of drug–therapy interactions. *BMC Pharmacology* **8** 5–8. (doi:10.1186/1471-2210-8-5)
- Nepusz T, Yu H & Paccanaro A 2012 Detecting overlapping protein complexes in protein–protein interaction networks. *Nature Methods* **9** 471–472. (doi:10.1038/nmeth.1938)
- Newman ME 2006 Modularity and community structure in networks. *PNAS* **103** 8577–8582. (doi:10.1073/pnas.0601602103)
- Ngounou Wetie AG, Sokolowska I, Woods AG, Roy U, Deinhardt K & Darie CC 2013 Protein–protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches. *Cellular and Molecular Life Sciences* [in press].
- Osborn O & Olefsky JM 2012 The cellular and signaling networks linking the immune system and metabolism in disease. *Nature Medicine* **18** 363–374. (doi:10.1038/nm.2627)
- Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M *et al.* 2007 Array express – a public database of microarray experiments and gene expression profiles. *Nucleic Acids Research* **35** D747–D750. (doi:10.1093/nar/gkl995)
- Patel L & Clayton PE 2012 Predicting response to growth hormone treatment. *Indian Journal of Pediatrics* **79** 229–237.
- Pietiläinen KH, Rog T, Seppanen-Laakso T, Virtue S, Gopalacharyulu P, Tang J, Rodriguez-Cuenca S, Maciejewski A, Naukkarinen J, Ruskeepaa AL *et al.* 2011 Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. *PLoS Biology* **9** e1000623. (doi:10.1371/journal.pbio.1000623)
- Pujol A, Mosca R, Farres J & Aloy P 2010 Unveiling the role of network and systems biology in drug discovery. *Trends in Pharmacological Sciences* **31** 115–123. (doi:10.1016/j.tips.2009.11.006)
- Ranke MB 2013 Treatment of children and adolescents with idiopathic short stature. *Nature Reviews Endocrinology* **9** 325–334.
- Ranke MB & Lindberg A 2011 The basis for optimising growth with growth hormone usage in children with idiopathic short stature: analysis of data from KIGS (Pfizer International Growth Study Database). *Hormone Research in Paediatrics* **76** (Suppl 3) 48–50. (doi:10.1159/000330160)
- Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Bertsson-Wikland K & Price DA 1999 Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. *Journal of Clinical Endocrinology and Metabolism* **84** 1174–1183.
- Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Bertsson-Wikland K & Price DA 2000 Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. *Journal of Clinical Endocrinology and Metabolism* **85** 4212–4218.
- Rohde KH, Veiga DF, Caldwell S, Balazsi G & Russell DG 2012 Linking the transcriptional profiles and the physiological states of *Mycobacterium tuberculosis* during an extended intracellular infection. *PLoS Pathogens* **8** e1002769. (doi:10.1371/journal.ppat.1002769)
- Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, Cotsapas C & Daly MJ 2011 Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. *PLoS Genetics* **7** e1001273. (doi:10.1371/journal.pgen.1001273)
- Santiago JA & Potashkin JA 2013 Shared dysregulated pathways lead to Parkinson's disease and diabetes. *Trends in Molecular Medicine* **19** 176–186. (doi:10.1016/j.molmed.2013.01.002)
- Savill SA, Leitch HF, Daly AK, Harvey JN & Thomas TH 2010 Polymorphisms in the tropomyosin TPM1 short isoform promoter alter gene expression and are associated with increased risk of metabolic syndrome. *American Journal of Hypertension* **23** 399–404. (doi:10.1038/ajh.2009.278)
- Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Grone HJ *et al.* 2006 Modular activation of nuclear factor- κ B transcriptional programs in human diabetic nephropathy. *Diabetes* **55** 2993–3003. (doi:10.2337/db06-0477)
- Senniappan S, Shanti B, James C & Hussain K 2012 Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. *Journal of Inherited Metabolic Disease* **35** 589–601. (doi:10.1007/s10545-011-9441-2)
- Sethi JK & Vidal-Puig AJ 2007 Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. *Journal of Lipid Research* **48** 1253–1262.
- Smoot ME, Ono K, Ruscheinski J, Wang PL & Ideker T 2011 Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics* **27** 431–432. (doi:10.1093/bioinformatics/btq675)
- Sookoian S & Pirola CJ 2013 Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic fatty liver disease. *PLoS ONE* **8** e58895. (doi:10.1371/journal.pone.0058895)
- Stark C, Breitkreutz BJ, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS, Nixon J, Van Auken K, Wang X, Shi X *et al.* 2011 The BioGRID interaction database: 2011 update. *Nucleic Acids Research* **2011** D698–D704. (doi:10.1093/nar/gkq1116)
- Stevens A, Clayton P, Tato L, Yoo HW, Rodriguez-Arnao MD, Skorodok J, Ambler GR, Zignani M, Zieschang J, Della CG *et al.* 2013a Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. *Pharmacogenomics Journal* [in press]. (doi:10.1038/tpj.2013.14)
- Stevens A, Cosgrove KE, Padidela R, Skae MS, Clayton PE, Banerjee I & Dunne MJ 2013b Can network biology unravel the aetiology of congenital hyperinsulinism? *Orphanet Journal of Rare Diseases* **8** 21–28. (doi:10.1186/1750-1172-8-21)
- Stevens A, De Leonibus C, Destenaves B, Rodriguez-Arnao MD, Ambler GR, Raelson J, Chatelain P & Clayton P 2013c Gene expression networks associated with changes in serum insulin, insulin-like growth factor-I, and growth in growth hormone (GH)-treated children with GH deficiency. *Endocrine Reviews* **34** FP20–FP26.
- Stevens A, Hanson D, Whatmore A, Destenaves B, Chatelain P & Clayton P 2013d Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks. *BMC Genomics* **14** 547. (doi:10.1186/1471-2164-14-547)
- Strafella AP 2013 Anatomical and functional connectivity as a tool to study brain networks in Parkinson's disease. *Movement Disorders* **28** 411–412. (doi:10.1002/mds.25320)
- Sun J & Zhao Z 2010 A comparative study of cancer proteins in the human protein–protein interaction network. *BMC Genomics* **11** (Suppl 3) S5. (doi:10.1186/1471-2164-11-S3-S5)
- Szabo PM, Butz H, Igaz P, Racz K, Hunyady L & Patocs A 2013 Minireview: MIRMomics in endocrinology: a novel approach for modeling endocrine diseases. *Molecular Endocrinology* **27** 573–585. (doi:10.1210/me.2012-1220)
- Szalai-Beko M, Palotai R, Szappanos B, Kovacs IA, Papp B & Csérmely P 2012 ModuLand plug-in for Cytoscape: determination of hierarchical layers of overlapping network modules and community centrality. *Bioinformatics* **28** 2202–2204. (doi:10.1093/bioinformatics/bts352)

- Takarabe M, Shigemizu D, Kotera M, Goto S & Kanehisa M 2011 Network-based analysis and characterization of adverse drug–drug interactions. *Journal of Chemical Information and Modeling* **51** 2977–2985. (doi:10.1021/ci200367w)
- Tang J & Aittokallio T 2013 Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. *Current Pharmaceutical Design* [in press].
- Thomas S & Bonchev D 2010 A survey of current software for network analysis in molecular biology. *Human Genomics* **4** 353–360. (doi:10.1186/1479-7364-4-5-353)
- Thompson JL & Nelson AJ 2011 Middle childhood and modern human origins. *Human Nature* **22** 249–280. (doi:10.1007/s12110-011-9119-3)
- Tomar N & De RK 2013 Comparing methods for metabolic network analysis and an application to metabolic engineering. *Gene* **521** 1–14. (doi:10.1016/j.gene.2013.03.017)
- Toubiana D, Fernie AR, Nikoloski Z & Fait A 2013 Network analysis: tackling complex data to study plant metabolism. *Trends in Biotechnology* **31** 29–36. (doi:10.1016/j.tibtech.2012.10.011)
- Villa-Vialaneix N, Liaubet L, Laurent T, Cherel P, Gamot A & Sancristobal M 2013 The structure of a gene co-expression network reveals biological functions underlying eQTLs. *PLoS ONE* **8** e60045. (doi:10.1371/journal.pone.0060045)
- Vlahou A 2013 Network views for personalized medicine. *Proteomics. Clinical Applications* **7** (5–6) 384–387. (doi:10.1002/prca.201200121)
- Watkins SM, Reifsnnyder PR, Pan HJ, German JB & Leiter EH 2002 Lipid metabolome-wide effects of the PPAR γ agonist rosiglitazone. *Journal of Lipid Research* **43** 1809–1817. (doi:10.1194/jlr.M200169-JLR200)
- Werner T 2008 Bioinformatics applications for pathway analysis of microarray data. *Current Opinion in Biotechnology* **19** 50–54. (doi:10.1016/j.copbio.2007.11.005)
- Yamaga R, Ikeda K, Horie-Inoue K, Ouchi Y, Suzuki Y & Inoue S 2013 RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites. *Hormones & Cancer* **4** 222–232. (doi:10.1007/s12672-013-0140-3)
- Yamauchi T, Ueki K, Tobe K, Tamemoto H, Sekine N, Wada M, Honjo M, Takahashi M, Takahashi T, Hirai H *et al.* 1997 Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. *Nature* **390** 91–96. (doi:10.1038/36369)
- Youngs N, Penfold-Brown D, Drew K, Shasha D & Bonneau R 2013 Parametric Bayesian priors and better choice of negative examples improve protein function prediction. *Bioinformatics* **29** 1190–1198. (doi:10.1093/bioinformatics/btt110)
- Zhang M, Zhu C, Jacomy A, Lu LJ & Jegga AG 2011 The orphan disease networks. *American Journal of Human Genetics* **88** 755–766. (doi:10.1016/j.ajhg.2011.05.006)
- Zhang J, Ni S, Xiang Y, Parvin JD, Yang Y, Zhou Y & Huang K 2013 Gene co-expression analysis predicts genetic aberration loci associated with colon cancer metastasis. *International Journal of Computational Biology and Drug Design* **6** 60–71. (doi:10.1504/IJCBDD.2013.052202)

Received in final form 19 August 2013

Accepted 1 October 2013

Accepted Preprint published online 1 October 2013